These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16972272)

  • 1. Corticotropin-releasing factor (CRF) receptor type 2 in the human stomach: protective biological role by inhibition of apoptosis.
    Chatzaki E; Lambropoulou M; Constantinidis TC; Papadopoulos N; Taché Y; Minopoulos G; Grigoriadis DE
    J Cell Physiol; 2006 Dec; 209(3):905-11. PubMed ID: 16972272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible involvement of corticotropin-releasing factor receptor signaling on vascular inflammation.
    Inada Y; Ikeda K; Tojo K; Sakamoto M; Takada Y; Tajima N
    Peptides; 2009 Feb; 30(2):365-72. PubMed ID: 19026699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
    Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
    Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells.
    Kageyama K; Kimura R; Suga S; Ogawa Y; Suda T; Wakui M
    Peptides; 2006 Jul; 27(7):1814-9. PubMed ID: 16513211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2.
    Tsatsanis C; Androulidaki A; Dermitzaki E; Gravanis A; Margioris AN
    J Cell Physiol; 2007 Mar; 210(3):774-83. PubMed ID: 17117478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous expression and in vitro study of CRF-related peptides and CRF receptors in the rat gastric antrum.
    Porcher C; Peinnequin A; Pellissier S; Meregnani J; Sinniger V; Canini F; Bonaz B
    Peptides; 2006 Jun; 27(6):1464-75. PubMed ID: 16337313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of the corticotropin-releasing factor (CRF) type 2 receptor in CRF-induced thyrotropin release by the amphibian pituitary gland.
    Okada R; Miller MF; Yamamoto K; De Groef B; Denver RJ; Kikuyama S
    Gen Comp Endocrinol; 2007 Feb; 150(3):437-44. PubMed ID: 17188689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mediation of burn-induced hypermetabolism by CRF receptor-2 activity.
    Chance WT; Dayal R; Friend LA; Thomas I; Sheriff S
    Life Sci; 2007 Feb; 80(11):1064-72. PubMed ID: 17222429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists.
    de Groote L; Peñalva RG; Flachskamm C; Reul JM; Linthorst AC
    J Neurochem; 2005 Jul; 94(1):45-56. PubMed ID: 15953348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropeptide urocortin 1 and its receptors are expressed in the human liver.
    Simopoulos C; Christodoulou E; Lambropoulou M; Tsaroucha AK; Kakolyris S; Polychronidis A; Karayiannakis AJ; Chatzaki E
    Neuroendocrinology; 2009; 89(3):315-26. PubMed ID: 19096201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional CRF receptors in BON cells stimulate serotonin release.
    von Mentzer B; Murata Y; Ahlstedt I; Lindström E; Martínez V
    Biochem Pharmacol; 2007 Mar; 73(6):805-13. PubMed ID: 17184738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urocortin expression is downregulated in human endometrial carcinoma.
    Florio P; De Falco G; Leucci E; Torricelli M; Torres PB; Toti P; Dell'Anna A; Tiso E; Santopietro R; Leoncini L; Petraglia F
    J Endocrinol; 2006 Jul; 190(1):99-105. PubMed ID: 16837614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart.
    Kimura Y; Takahashi K; Totsune K; Muramatsu Y; Kaneko C; Darnel AD; Suzuki T; Ebina M; Nukiwa T; Sasano H
    J Clin Endocrinol Metab; 2002 Jan; 87(1):340-6. PubMed ID: 11788672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Over-expression of neuropeptide urocortin and its receptors in human allergic nasal mucosa.
    Kim TH; Lee SH; Lee HM; Lee SH; Lee SW; Kim WJ; Park SJ; Kim YS; Choe H; Hwang HY; Yoo IO
    Laryngoscope; 2007 Sep; 117(9):1513-8. PubMed ID: 17597629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urocortins and the regulation of gastrointestinal motor function and visceral pain.
    Martinez V; Wang L; Million M; Rivier J; Taché Y
    Peptides; 2004 Oct; 25(10):1733-44. PubMed ID: 15476940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system.
    Hashimoto K; Nishiyama M; Tanaka Y; Noguchi T; Asaba K; Hossein PN; Nishioka T; Makino S
    Peptides; 2004 Oct; 25(10):1711-21. PubMed ID: 15476938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways.
    Tezval H; Jurk S; Atschekzei F; Serth J; Kuczyk MA; Merseburger AS
    Prostate; 2009 Mar; 69(4):443-8. PubMed ID: 19058138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.
    Beyermann M; Heinrich N; Fechner K; Furkert J; Zhang W; Kraetke O; Bienert M; Berger H
    Br J Pharmacol; 2007 Jul; 151(6):851-9. PubMed ID: 17533422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microinjection of urocortin into the rat nucleus tractus solitarii decreases arterial blood pressure.
    Yamazaki T; Waki H; Kohsaka A; Nakamura T; Cui H; Yukawa K; Maeda M
    Auton Neurosci; 2008 Nov; 142(1-2):51-4. PubMed ID: 18804421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.